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INTRODUCTION
Anemia is a common finding in patients with chronic kidney 
disease (CKD), and its prevalence and severity are known to in-
crease as renal function decreases. In addition, anemia is close-
ly associated with a wide range of clinical symptoms and signs, 
resulting in poor quality of life and increased risk of morbidity 
and mortality in these patients.1-5
Recently, accumulating evidence indicates that vitamin D 
has pleiotropic effects in various organ systems based on the 
distribution of vitamin D receptors in the whole body.6 In addi-
tion to its well-known effects on bone and mineral metabolism, 
vitamin D has been revealed to play a protective role in a num-
ber of chronic diseases, including CKD-associated anemia.7 In 
fact, previous studies using data from the Study to Evaluate Ear-
ly Kidney Disease and the Third National Health and Nutrition 
Examination Survey showed that vitamin D deficiency was sig-
nificantly and independently associated with anemia in pa-
tients with CKD who not require dialysis.8,9 However, the rela-
tionship between serum 25-hydroxyvitamin D [25(OH)D3] and 
hemoglobin (Hb) concentrations has not been extensively ex-
Association between Vitamin D Deficiency and  
Anemia in Patients with End-Stage Renal Disease:  
A Cross-Sectional Study
Yung Ly Kim1, Hyunwook Kim1, Young Eun Kwon1, Dong-Ryeol Ryu2, Mi Jung Lee1, Kyung Sook Park1,  
Han Jak Ryu1, Jung Tak Park1, Hyung Jung Oh1, Seung Hyeok Han1, Tae-Hyun Yoo1, and Shin-Wook Kang3
1Department of Internal Medicine, Yonsei University College of Medicine, Seoul;
2Department of Internal Medicine, School of Medicine, Ewha Womans University, Seoul;
3Department of Internal Medicine, College of Medicine, Severance Biomedical Science Institute, Brain Korea 21 PLUS, Yonsei University, Seoul, Korea.
Purpose: Despite new treatment strategies, anemia remains the most prevalent complication in patients with end-stage renal 
disease (ESRD). We investigated whether 25-hydroxyvitamin D [25(OH)D3] deficiency was associated with anemia in ESRD pa-
tients.
Materials and Methods: We reviewed the medical records of 410 ESRD patients who had undergone renal transplantation (RTx) at 
Yonsei University Health System and who had 25(OH)D3 levels measured at the time of RTx. Patients were divided into two groups 
based on baseline 25(OH)D3 concentrations: group 1, 25(OH)D3 levels <10 ng/mL; and group 2, 25(OH)D3 levels ≥10 ng/mL.
Results: Using multivariate regression models, 25(OH)D3, age, and erythrocyte-stimulating agent (ESA) dose were found to be 
significantly associated with hemoglobin (Hb) levels [25(OH)D3: β=0.263, p<0.001; age: β=0.122, p=0.010; ESA dose: β=-0.069, 
p=0.005]. In addition, logistic regression analysis revealed that patients in group 1 had a significantly higher risk for developing 
anemia (Hb level <10 g/dL) compared to group 2 patients, even after adjusting for potential risk factors for anemia (odds ratio=3.857; 
confidence interval=1.091–13.632; p=0.036).
Conclusion: 25(OH)D3 deficiency was significantly associated with anemia in patients with ESRD. Randomized controlled trials 
are needed to determine whether vitamin D supplementation can improve anemia in these patients.
Key Words:  Vitamin D deficiency, anemia, end-stage renal disease
Yonsei Med J 2016 Sep;57(5):1159-1164
http://dx.doi.org/10.3349/ymj.2016.57.5.1159
Original Article 
pISSN: 0513-5796 · eISSN: 1976-2437
Received: October 5, 2015   Revised: January 6, 2016
Accepted: January 7, 2016
Corresponding author: Shin-Wook Kang, MD, PhD, Department of Internal Med-
icine, College of Medicine, Severance Biomedical Science Institute, Brain Korea 
21 PLUS, Yonsei University, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
Tel: 82-2-2228-1959, Fax: 82-2-393-6884, E-mail: kswkidney@yuhs.ac
•The authors have no financial conflicts of interest.
© Copyright: Yonsei University College of Medicine 2016
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
http://dx.doi.org/10.3349/ymj.2016.57.5.11591160
Vitamin D Deficiency and Anemia in ESRD Patients
plored in patients with end-stage renal disease (ESRD).
In this study, we attempted to elucidate the correlation of 
25(OH)D3 with anemia in relatively healthy patients with ESRD 
who were admitted to the hospital for renal transplantation 
(RTx). Moreover, the independent impact of 25(OH)D3 on ane-
mia was clarified in these patients.
MATERIALS AND METHODS
Patients
We reviewed the medical records of 423 patients with ESRD 
who had undergone RTx at Yonsei University Health System in 
Seoul, Korea (latitude: 37.5°N; average annual sunshine: 5.8 
hours per day) between April 2002 and December 2008 and 
whose 25(OH)D3 levels were measured at the next date of hos-
pital admission for RTx (about 1–2 weeks before RTx). Among 
these patients, 13 were excluded for being less than 18 years old 
(n=6) or more than 70 years old (n=7). Thus, the final analysis 
involved 410 RTx patients. No patients with acute illness were 
included in the current study. All participants were from an 
ethnically homogeneous Korean population.
Ethics statement
This study was approved by the Institutional Review Board 
(IRB) of Yonsei University Health System Clinical Trial Center 
(IRB No. 4-2014-0447). All patients who participated in the cur-
rent study were aware of this investigation. However, as the 
present study was a retrospective medical record-based study 
and the study subjects were de-identified, the IRB waived the 
need for written consent from the patients.
Laboratory and clinical data
Although 1,25(OH)2D3 is the active form of vitamin D, its half-
life is only 4–6 hours in circulation. In the clinical field, there-
fore, 25(OH)D3 is regarded as the best index to assess vitamin 
D status due to its long half-life of approximately 3 weeks.10 The 
serum 25(OH)D3 concentrations were determined at the time of 
RTx via a radioimmunoassay method using the 25-HYDROXYVI-
TAMIN D 125I RIA KIT (68100E; DiaSorin Inc., Stillwater, MN, 
USA).11 According to the opinion of most experts, vitamin D de-
ficiency is defined as serum 25(OH)D3 levels <10 ng/mL (25 
nmol/L), vitamin D insufficiency as 25(OH)D3 levels of 10–29 
ng/mL (25–72 nmol/L), and vitamin D sufficiency as 25(OH)D3 
levels ≥30 ng/mL (73 nmol/L).10,12-17 As there were no patients 
with vitamin D sufficiency, the patients were divided into two 
groups for analysis: group 1, 25(OH)D3 <10 ng/mL and group 2, 
25(OH)D3 ≥10 ng/mL.
Demographic and clinical data at the time of RTx were re-
corded, including age, sex, dialysis modality before RTx, dura-
tion of dialysis, comorbidities, season at the time of RTx, and 
erythrocyte-stimulating agent (ESA) dose. To further study the 
association between 25(OH)D3 levels and ESA requirements, 
the ESA dose/Hb index was calculated by dividing the monthly 
ESA dose (units) by the Hb concentration. The results of the fol-
lowing biochemical laboratory tests were also collected: Hb, in-
tact parathyroid hormone (iPTH), serum iron, total iron-bind-
ing capacity (TIBC), transferrin saturation (TSAT), ferritin, 
alkaline phosphatase (ALP), serum phosphate, calcium, albu-
min, estimated glomerular filtration rate (eGFR), and high-sen-
sitivity C-reactive protein (hs-CRP) levels.
Statistical analyses
Statistical analysis was performed using SPSS version 20.0 
(SPSS Inc., Chicago, IL, USA). Continuous variables are ex-
pressed as mean±standard deviation or median±interquartile 
range for skewed data. The Kolmogorov-Smirnov test was used 
to analyze the normality of the distribution of measured parame-
ters, and categorical variables are presented as a number (per-
centage). The patients were divided into two groups based on se-
rum 25(OH)D3 concentrations (<10 ng/mL and ≥10 ng/mL). 
The differences between the two groups were determined us-
ing Student’s t test or the Mann-Whitney U test for continuous 
variables and the chi-square test for categorical variables. The 
relationship between Hb and 25(OH)D3 levels was assessed 
using Pearson’s correlation analysis. Univariate and multivari-
ate linear regression analyses were also performed to deter-
mine the independent correlates of anemia. A logistic regres-
sion analysis was used to estimate odds ratios (OR) and to id-
entify independent risk factors for anemia. The National Kidney 
Foundation-Kidney Disease Outcomes Quality Initiative (NKF-
KDOQI) guidelines (2012) recommended that Hb targets should 
be in the range of 10.0–11.5 g/dL, regardless of whether the pa-
tients were receiving dialysis.18 Therefore, we defined anemia as 
an Hb level of <10 g/dL. In all cases, a p-value of <0.05 was consid-
ered to be statistically significant.
RESULTS
Baseline characteristics
Demographic, clinical, and biochemical data are shown in Ta-
ble 1. The mean age was 40.7±11.4 years, and 262 patients 
(63.9%) were male. The mean serum 25(OH)D3 concentration 
was 11.1±6.4 ng/mL, while the mean 25(OH)D3 level was 6.5±1.8 
ng/mL in group 1 and 17.2±5.6 ng/mL in group 2. There were no 
differences in age, dialysis modality, season at the time of RTx, 
and comorbidities between the two groups. However, the fol-
lowing factors were significantly different between the two 
groups. Group 2 had a higher proportion of men than group 1 
(69.9%; p=0.003). The proportion of patients who met the crite-
ria for anemia (60.2%; p<0.001) and ESA use (53.8%; p=0.013) 
was significantly higher in group 1. Moreover, the monthly ESA 
dose was significantly higher in group 1 (20656.2±17627.7; 
p=0.003).
As seen in Table 1, serum phosphate, calcium, and albumin 
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concentrations were significantly lower in group 1 than in 
group 2. In contrast, there were no significant differences in se-
rum levels of iPTH, serum iron, TIBC, TSAT, ferritin, ALP, eGFR, 
and hs-CRP.
Predictors of anemia
On univariate linear regression analysis, Hb concentration was 
found to be significantly correlated with serum 25(OH)D3 level 
(β=0.292; p<0.001), age (β=0.147; p=0.003), ESA dose (β=-0.177; 
p<0.001), and log iPTH (β=-0.102; p=0.039). The associations be-
Table 1. Baseline Characteristics of Patients According to 25(OH)D3 Levels
Variable Total
Group 1




n (%) 410 171 (41.7%) 239 (58.7%)
Demographic data
Age (yrs) 40.7±11.4 40.8±10.5 41.3±11.3 0.662
Male sex, n (%) 262 (63.9%) 95 (55.5%) 167 (69.9%) 0.003
Anemia (Hb <10 g/dL) 175 (42.7%) 103 (60.2%) 72 (30.1%) <0.001
Dialysis (%) 0.395
Hemodialysis 199 (48.5%) 58 (34.0%) 162 (68.8%)
Peritoneal dialysis 78 (19.0%) 22 (24.5%) 14 (6.3%)
No dialysis 133 (32.4%) 91 (53.2%) 63 (26.3%)
Duration of dialysis (months) 20.4±37.3 16.8±33.1 23.3±40.5 0.236
Season of RTx 0.718
Spring 90 (22.0%) 51 (29.8%) 39 (16.3%)
Summer 107 (26.1%) 29 (17.0%) 78 (32.6%)
Autumn 101 (24.6%) 37 (21.6%) 64 (26.8%)
Winter 112 (27.3%) 54 (31.6%) 58 (24.3%)
Co-morbidities (%)
Diabetes 77 (18.8%) 38 (22.2%) 39 (16.3%) 0.132
Hypertension 364 (88.8%) 155 (90.6%) 209 (87.4%) 0.313
Medications
Use of ESA 191 (46.5%) 92 (53.8%) 99 (41.4%) 0.013
Vitamin D supplement 87 (21.2%) 33 (19.3%) 54 (22.6%) 0.463
Oral iron supplement 360 (87.8%) 156 (91.2%) 204 (85.4%) 0.073
IV iron supplement 68 (16.6%) 42 (25.6%) 26 (10.9%) <0.001
ESA dose, units/months 16956.5±17252.2 20656.2±17627.7 10970.7±16146.2 0.003
ESA dose/Hb index 1842.9±1935.3 2227.5±1929.9 1133.0±1718.4 0.001
Biochemical data
25(OH)D3 (ng/mL; median) 11.1±6.4 6.5±1.8 17.2±5.6 <0.001
Hb (g/dL) 9.9±1.9 9.7±2.0 10.5±1.6 <0.001
iPTH (pg/mL; median) 168.3±164.9 152.3±220.7 225.2±243.0 0.677
Serum iron (ug/dL) 77.1±55.3 77.9±47.1 72.5±58.5 0.814
TIBC (µg/dL) 202.8±85.6 194.1±84.1 209.9±86.7 0.785
TSAT (%) 38.0±86.4 33.3±21.8 41.3±11.6 0.357
Ferritin (ng/mL) 193.2±143.9 190.6±156.2 196.5±128.3 0.391
ALP (IU/L) 60.6±26.1 58.1±23.3 63.7±27.0 0.676
Phosphate (mg/dL) 5.3±1.4 5.0±1.4 5.7±1.3 0.001
Calcium (mg/dL) 7.7±1.0 7.4±0.9 8.1±1.0 0.001
Albumin (g/dL) 3.9±0.4 3.8±0.4 4.0±0.4 0.001
eGFR (mL/min/1.73 m²) 4.9±2.7 4.9±2.2 4.7±1.7 0.567
hs-CRP (mg/L; median) 0.15±2.2 0.13±2.3 0.19±2.0 0.560
25(OH)D3, 25-hydroxyvitamin D; Hb, hemoglobin; RTx, renal transplantation; IV, intravenous; ESA, erythrocyte stimulating agent; iPTH, intact parathyroid hor-
mone; TIBC, total iron binding capacity; TSAT, transferrin saturation; ALP, alkaline phosphatase; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivi-
ty C-reactive protein.
Results are expressed as mean±standard deviation, median±interquartile range, or n (%).
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tween Hb concentration and serum 25(OH)D3 level (β=0.263; 
p<0.001), age (β=0.122; p=0.010), and ESA dose (β=-0.069; 
p=0.005) remained significant on multivariate linear regression 
analysis (Table 2). Serum 25(OH)D3 concentration was also 
significantly associated with ESA resistance, assessed by the ESA 
dose/Hb index, on both univariate analysis (β=-0.176; p<0.001) 
and multivariate analysis (β=-0.047; p<0.001) (Table 3).
Correlation between vitamin D deficiency and anemia
Pearson’s correlation analysis revealed a significant correlation 
between 25(OH)D3 and Hb levels (r=0.292; p<0.001). Hb level 
also significantly correlated with albumin (r=0.267; p<0.001) 
and calcium levels (r=0.309; p=0.040).
Correlation between vitamin D deficiency  
and ESA resistance
Pearson’s correlation analysis revealed a significant negative 
correlation between ESA dose/Hb index and 25(OH)D3 level 
(r=-0.176; p<0.001). ESA dose/Hb level also negatively correlat-
ed with Hb (r=-0.329; p<0.001), albumin (r=-0.172; p<0.001), 
and calcium levels (r=-0.099; p=0.046).
Effect of vitamin D deficiency on anemia
Logistic regression analysis revealed that patients in group 1 
had a significantly higher risk for developing anemia than group 
2 patients, even after adjusting for age, ESA dose, log iPTH, 
phosphate, ALP, log hs-CRP, ferritin, serum iron, TIBC, TSAT 
levels, sex, diabetes, and smoking [OR=3.857; 95% confidence 
interval (CI)=1.091–13.632; p=0.036] (Table 4).
DISCUSSION
Previous studies have demonstrated the association of serum 
vitamin D and Hb levels in patients with CKD who do not re-
quire dialysis;8,19 however, the impact of vitamin D deficiency on 
anemia has not been extensively explored in patients with 
ESRD.
In this study, we demonstrated that patients with 25(OH)D3 
levels <10 ng/dL had a higher risk of developing anemia than 
patients with 25(OH)D3 levels ≥10 ng/dL. This association re-
mained significant even after adjusting for potentially impor-
Table 2. Associations between Hb and Clinical/Biochemical Parameters
Univariate analysis Multivariate analysis
β p value β p value
25(OH)D3 0.292 <0.001 0.263 <0.001
Age 0.147 0.003 0.122 0.010
ESA dose -0.177 <0.001 -0.069 0.005
Log iPTH -0.102 0.039 -1.470 0.142
Phosphate -0.048 0.331 - -
ALP 0.051 0.299 - -
Log hs-CRP -0.094 0.440 - -
Ferritin 0.030 0.541 - -
Serum iron -0.031 0.535 - -
TIBC -0.044 0.369 - -
TSAT 0.033 0.503 - -
Sex (male) 0.007 0.895 - -
Diabetes (yes) 0.075 0.131 - -
Smoking (yes) 0.059 0.232 - -
Hb, hemoglobin; 25(OH)D3, 25-hydroxyvitamin D; ESA, erythrocyte stimulat-
ing agent; iPTH, intact parathyroid hormone; ALP, alkaline phosphatase; hs-
CRP, high-sensitivity C-reactive protein; TIBC, total iron binding capacity; 
TSAT, transferrin saturation.
Table 3. Associations between ESA Dose/Hb Index and Clinical/Bio-
chemical Parameters
Univariate analysis Multivariate analysis
β p value β p value
25(OH)D3 -0.176 <0.001 -0.047 <0.001
Age -0.064 0.197 - -
Log iPTH 0.043 0.385 - -
Phosphate 0.137 0.006 0.022 0.101
ALP -0.022 0.663 - -
Log hs-CRP -0.104 0.392 - -
Ferritin -0.033 0.499 - -
Serum iron -0.096 0.053 - -
TIBC -0.070 0.159 - -
TSAT -0.047 0.340 - -
Sex (male) 0.096 0.052 - -
Diabetes (yes) -0.103 0.037 -0.024 0.072
Smoking (yes) -0.017 0.733 - -
ESA, erythrocyte stimulating agent; Hb, hemoglobin; 25(OH)D3, 25-hydroxyvi-
tamin D; iPTH, intact parathyroid hormone; ALP, alkaline phosphatase; hs-
CRP, high-sensitivity C-reactive protein; TIBC, total iron binding capacity; 
TSAT, transferrin saturation.
Table 4. Risk Factors for Developing Anemia (Hb <10 g/dL)
Variable OR (95% CI) p value
25(OH)D3 <10 vs. ≥10 3.857 (1.091–13.632) 0.036
Age (per 1-year increase) 0.971 (0.919–1.027) 0.307
ESA dose (per 1-unit increase) 1.000 (1.000–1.000) 0.211
Log iPTH (per 1-pg/mL increase) 1.440 (0.807–2.569) 0.217
Phosphate (per 1-mg/dL increase) 0.815 (0.498–1.334) 0.417
ALP (per 1-IU/L increase) 1.005 (0.979–1.032) 0.689
Log hs-CRP (per 1-mg/L increase) 0.890 (0.515–1.539) 0.677
Ferritin (per 1-ng/mL increase) 0.996 (0.992–1.001) 0.132
Serum iron (per 1-ug/dL increase) 1.003 (0.987–1.020) 0.715
TIBC (per 1-ug/dL increase) 0.998 (0.987–1.009) 0.706
TSAT (per 1% increase) 0.312 (0.034–2.875) 0.304
Sex (male vs. female) 0.184 (0.033–1.015) 0.052
Diabetes (yes vs. no) 0.337 (0.080–1.418) 0.138
Smoking (yes vs. no) 0.215 (0.041–1.142) 0.071
OR, odds ratio; Hb, hemoglobin; CI, confidence interval; 25(OH)D3, 25-hy-
droxyvitamin D; ESA, erythrocyte stimulating agent; iPTH, intact parathyroid 
hormone; ALP, alkaline phosphatase; hs-CRP, high-sensitivity C-reactive pro-
tein; TIBC, total iron binding capacity; TSAT, transferrin saturation.
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tant risk factors for anemia. These findings are of great clinical 
significance, as anemia is very common in CKD patients and is 
associated with negative clinical outcomes.20-22 The NKF-KDOQI 
guidelines (2012) recommended 10 g/dL as the lowest Hb level 
in CKD patients.18 Hb levels <10 g/dL can increase the need for 
transfusion and the risks of cardiovascular complications and 
mortality in CKD patients.23,24 Several factors or medical comor-
bidities have been identified as risk factors for anemia. Based 
on our data, we suggest that vitamin D deficiency, a modifiable 
condition, could be an additional risk factor for anemia in ESRD 
patients.
Several potential mechanisms could explain the association 
between vitamin D deficiency and anemia in ESRD patients. 
Several studies have found that vitamin D exerts a direct stimu-
latory action on erythroid precursor cells in CKD patients. The 
burst-forming unit-erythroid (BFU-E) assay revealed that com-
bined low doses of erythropoietin and vitamin D significantly 
increased proliferation of mononuclear cells isolated from the 
peripheral blood of patients with CKD compared to low-dose 
erythropoietin alone.25 Moreover, BFU-E proliferation was fur-
ther potentiated by high-dose vitamin D,26 although this was 
not observed with cells isolated from healthy subjects. Taken 
together, these findings suggest that vitamin D has a direct ef-
fect on erythroid precursor proliferation in CKD patients yet not 
in patients with normal renal function.
In addition, there is growing evidence that inflammatory cy-
tokines influence erythropoiesis in CKD patients.27 Moreover, 
vitamin D deficiency was associated with secondary hyper-
parathyroidism, which is known to induce bone marrow fibro-
sis and suppress erythropoiesis in CKD patients.28 Taken to-
gether, vitamin D seems to be involved in erythropoiesis in 
multiple ways in CKD patients, including directly stimulating 
the proliferation of erythropoietic cells, improving iron availabili-
ty by inhibiting inflammatory cytokines and hepcidin produc-
tion, and suppressing parathyroid hormone concentrations.
In this study, vitamin D deficiency was found to be an inde-
pendent risk factor for anemia in patients with ESRD, which is 
in agreement with the results of most previous studies of pa-
tients with early CKD and patients undergoing hemodialysis. 
Although no significant differences in serum hs-CRP and iPTH 
levels were found with respect to vitamin D deficiency, the con-
centrations of both were lower in patients with vitamin D defi-
ciency. Furthermore, Pearson’s correlation analysis revealed no 
relationships between Hb levels and serum hs-CRP, iPTH, or 
iron levels. Based on these findings, it seems likely that the 
weak association between inflammation, hyperparathyroid-
ism, and iron profiles with anemia in the present study was the 
result of our patients being relatively healthy and stable with 
minimal inflammation, acceptably controlled secondary hy-
perparathyroidism, and a good nutritional status.
This study had several limitations. First, the number of pa-
tients was relatively small. Second, as the study subjects were 
all Korean patients with ESRD, the associations of vitamin D 
with anemia and erythropoietin resistance may not be general-
izable to other populations. Finally, serum vitamin D concen-
trations were measured only once at the time of RTx; therefore, 
it was difficult to conclusively determine whether the changes 
in serum vitamin D levels had any influence on the changes in 
Hb concentrations and erythropoietin resistance.
In conclusion, vitamin D deficiency was prevalent in patients 
with ESRD undergoing RTx and was found to be independently 
associated with anemia and erythropoietin resistance. Further 
studies will be needed to verify the association of vitamin D de-
ficiency with anemia and erythropoietin resistance by evaluat-
ing the effect of vitamin D replacement in patients with ESRD.
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